Syage, Jack A.
Murray, Joseph A.
Green, Peter H. R.
Khosla, Chaitan
Funding for this research was provided by:
National Institutes of Health (R01 DK063158)
Article History
Received: 7 April 2017
Accepted: 19 July 2017
First Online: 28 July 2017
Compliance with ethical standards
:
: JAS is a founder of and owns stock in ImmunogenX. JAM has received grant support from the National Institutes of Health, Alvine Pharmaceuticals, and Alba Therapeutics; receives ongoing support from Oberkotter Foundation and Broad Medical Research Program at CCFA; serves on the advisory board of Celimmune, LLC and ImmunogenX; was a consultant to, BioLineRx, GlaxoSmithKline (GSK), Genentech, and Glenmark Pharmaceuticals Ltd; and is a consultant to ImmunosanT, Institute for Protein Design (PvP Biologics), Takeda Pharmaceutical Company, Ltd., Innovate Biopharmaceuticals, Inc., and Intrexon. PHRG is an advisor to ImmusanT and ImmunogenX. CK is a director of Protagonist Pharmaceuticals and an advisor to Sitari Pharmaceuticals and holds stock in both companies.